Trisha Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Trisha Das has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jimeng Sun
Department of Computer Science, University of Illinois Urbana-Champaign, Champaign, USA
2 shared publications Chufan Gao
Siebel School of Computing and Data Science, University of Illinois Urbana-Champaign, Urbana, USA
1 shared publication- Jathurshan Pradeepkumar
Siebel School of Computing and Data Science, University of Illinois Urbana-Champaign, Urbana, USA
1 shared publication Shivashankar Thati
Keiji AI, Seattle, USA
1 shared publication- Zifeng Wang
Keiji AI , Seattle, WA, 98115
1 shared publication
Latest Publications
- 4 March 2026
- Published by Springer Nature in Nature Health
- Vol. 1 (4) , 428-436
A large-scale database for clinical trial outcomes and features
- 4 March 2026
- Published by Springer Nature in Nature Health
- Vol. 1 (4) , 428-436
A large-scale database for clinical trial outcomes and features
- Open Access
- 4 August 2023
- Published by Association for Computing Machinery (ACM)
- p. 402-413
TWIN: Personalized Clinical Trial Digital Twin Generation
Clinical trial digital twins are virtual patients that reflect personal characteristics in a high degree of granularity and can be used to simulate various patient outcomes under different conditions. With the growth of clinical trial databases captured by Electronic Data Capture (EDC) systems, there is a growing interest in using machine learning models to generate digital twins. This can benefit the drug development process by reducing the sample size required for participant recruitment, improving patient outcome predictive modeling, and mitigating privacy risks when sharing synthetic clinical trial data. However, prior research has mainly focused on generating Electronic Healthcare Records (EHRs), which often assume large training data and do not account for personalized synthetic patient record generation. In this paper, we propose a sample-efficient method TWIN for generating personalized clinical trial digital twins. TWIN can produce digital twins of patient-level clinical trial records with high fidelity to the targeting participant's record and preserves the temporal relations across visits and events. We compare our method with various baselines for generating real-world patient-level clinical trial data. The results show that TWIN generates synthetic trial data with high fidelity to facilitate patient outcome predictions in low-data scenarios and strong privacy protection against real patients from the trials.
- 4 August 2023
- Published by Association for Computing Machinery (ACM)
- p. 402-413
Open AccessTWIN: Personalized Clinical Trial Digital Twin Generation
Clinical trial digital twins are virtual patients that reflect personal characteristics in a high degree of granularity and can be used to simulate various patient outcomes under different conditions. With the growth of clinical trial databases captured by Electronic Data Capture (EDC) systems, there is a growing interest in using machine learning models to generate digital twins. This can benefit the drug development process by reducing the sample size required for participant recruitment, improving patient outcome predictive modeling, and mitigating privacy risks when sharing synthetic clinical trial data. However, prior research has mainly focused on generating Electronic Healthcare Records (EHRs), which often assume large training data and do not account for personalized synthetic patient record generation. In this paper, we propose a sample-efficient method TWIN for generating personalized clinical trial digital twins. TWIN can produce digital twins of patient-level clinical trial records with high fidelity to the targeting participant's record and preserves the temporal relations across visits and events. We compare our method with various baselines for generating real-world patient-level clinical trial data. The results show that TWIN generates synthetic trial data with high fidelity to facilitate patient outcome predictions in low-data scenarios and strong privacy protection against real patients from the trials.